Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm signs LoI with Siro ClinPharm
Under the terms of the binding letter of intent, NeoPharm and Siro have agreed to negotiate in good faith the terms of a clinical research agreement pursuant to
Under the terms of the binding letter of intent, NeoPharm and Siro have agreed to negotiate in good faith the terms of a clinical research agreement pursuant to
Bill Worthen, president and CEO of Alsius, said: “This is the fourth contract we have been awarded by a major hospital group purchasing organization in the US. We
Dr Odlaug served as executive vice president and a member of the senior management committee at Fujisawa Healthcare until its merger with Yamanouchi in 2005, which resulted in
The results showed the efficacy of the Cooled ThermoCath (CTC) microwave catheter is durable for at least five years and the freedom from additional minimally invasive or surgical
The state-of-the-art facility produces Edwards’s Carpentier-Edwards Perimount tissue heart valve replacements, and also serves as the headquarters for Edwards’s Asia-Pacific operations. Donald Bobo, Jr, corporate vice president of
The therapeutic areas included in these awards are oncology, asthma, diabetes, rheumatology, and immunology or vaccines. Services to be provided include consulting, regulatory affairs, project management, field monitoring,
Indevus jointly granted the rights along with Rottapharm Madaus Group, an Italian pharmaceutical group, as required by a prior agreement between Indevus and Rottapharm Madaus. Indevus and Rottapharm
The company has also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of severe acute respiratory syndrome (SARS) vaccine candidates using
Mr Gemayel joins Altus Pharmaceuticals from Genzyme where he was executive vice president and a company officer. David Pendergast, who was serving as executive chairman, will continue as
This clinical study determines the safety and tolerability of AP24534, as well as its pharmacokinetics and its pharmacodynamics. Since all participants in the trial will have well-characterized malignancies,